Philip Morris International logo
  • Small text size
  • Medium text size
  • Large text size
  • Email
  • Print
  • PMI Global Site

Belgium

  • EN
  • NL
  • FR
                                                                                            
cc1=true;cc3=true;cc4=true; 
Belgium

Contact Us

Philip Morris Benelux BVBA
Berchemstadionstraat 72
2600 Berchem
Belgium

Careers

  • International Opportunities

Country Overview

Key Facts

Number of Employees: Approximately 200

Welcome to Philip Morris Benelux. In 1971, Philip Morris International acquired Achille Welle, later named Welltab, and in 1981, Welltab officially became Philip Morris Belgium. Our office is located in the Antwerp suburb of Berchem, and we currently employ a sales team of approximately 60 people. Our main brands include Marlboro, Belgium’s number one brand, and L&M.

Smoking and Health

Tobacco products, including cigarettes, are dangerous and addictive. There is overwhelming medical and scientific evidence that smoking causes lung cancer, heart disease, emphysema, and other serious diseases.

Addiction

All tobacco products are addictive. It can be very difficult to quit smoking, but this should not deter smokers who want to quit from trying to do so.

Secondhand Smoke
Public health officials have concluded that secondhand smoke from cigarettes causes serious diseases in non-smokers, including lung cancer and heart disease. We believe the public health conclusions on secondhand smoke are sufficient to support smoking restrictions in public places.

Effective Regulation
Philip Morris International (PMI) supports comprehensive regulation of tobacco products based on the principle of harm reduction.

To be effective, tobacco regulatory policy must be evidence-based, apply to all tobacco products, and should take into account the views of all legitimate stakeholders including public health authorities, government finance authorities, tobacco manufacturers, and other members of the tobacco supply chain.  Regulatory policy must consider the potential to trigger adverse consequences which undermine public health objectives, such as increasing the demand for illicit cigarettes. While we support comprehensive, effective tobacco regulation, we do not support regulation that prevents adults from buying and using tobacco products or that imposes unnecessary impediments to the operation of the legitimate tobacco market. In that regard, we oppose measures such as generic packaging, point of sale display bans, total bans on communications to adult consumers, and bans on the use of all ingredients in tobacco products. 

© 2002-2010 Philip Morris International Management SA